약물스크리닝을 통해 청신경종양 세포를 억제하는 유효물질의 발굴

The discovery of hit compounds inhibiting vestibular schwannoma cell growth using drug screening

Objectives : Our knowledge of the molecular biology of vestibular schwannomas (VS) and the development of novel medical therapies for their treatment are increasing. Although several anticancer drugs have been tested in VS, new medical therapies without toxicity are needed. Therefore, we investigated to identify novel hit compounds for potential inhibitors of VS growth using a cell-based screening assay. Method : HEI-193 cells and Nf2 knockout SC4 cells were used to investigate the inhibitory effects on VS cells. We investigated 2,300 FDA-approved / investigational drugs and natural compounds using a cell-based screening assay. Briefly, HEI-193 cells were plated in 96-well plates at 30% confluence and then the test compounds were added to each well at final concentration of 10μM with fresh growth medium. After 24 hour incubation, MTS assays were done to assess cell proliferation. Results : In primary screening, twenty three hit compounds were identified as potential inhibitors of VS growth from 2,320 compounds of FDA approved/ investigational drugs at a concentration of 10μM. The hit compounds were defined by > 50% reduction in VS growth. Conclusion : We identified several schwannoma growth inhibitory compounds for VS from a cellbased screening with 2,320 compounds. These kinds of pharmacologically well-characterized molecules can be readily translated to further preclinical studies for VS.